Ketamine-Assisted Psychotherapy: A Practical Guide for Medical Providers
Date: Sep 12, 2020
September 12 @ 4:00 pm - 5:00 pm
PART OF PSYCH CONGRESS CONFERENCE
Ketamine, an NMDA receptor antagonist, has now been FDA approved for treatment-resistant depression (TRD) in the intranasal form and is also available as an oral, intravenous, and intramuscular agent. This session will describe a rationale for the use of ketamine-assisted psychotherapy (KAP) for TRD, providing a historical context and examples of current theoretical stances. We will discuss which patients are good candidates for this therapy and provide extensive case examples. Practical issues related to KAP, including reimbursement and insurance as well as prevention of medication misuse, will also be addressed.